Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.09
-0.12 (-1.66%)
Nov 4, 2024, 4:00 PM EST - Market closed
Kezar Life Sciences Employees
Kezar Life Sciences had 58 employees as of December 31, 2023. The number of employees decreased by 26 or -30.95% compared to the previous year.
Employees
58
Change (1Y)
-26
Growth (1Y)
-30.95%
Revenue / Employee
$120,690
Profits / Employee
-$1,699,448
Market Cap
51.73M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Qilian International Holding Group | 298 |
Champions Oncology | 210 |
Cytosorbents | 186 |
Fortress Biotech | 186 |
Affimed | 76 |
Actinium Pharmaceuticals | 49 |
SCYNEXIS | 29 |
Protara Therapeutics | 27 |
KZR News
- 8 days ago - Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire
- 19 days ago - Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 19 days ago - Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - Business Wire
- 26 days ago - Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - Business Wire
- 4 weeks ago - US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Reuters
- 4 weeks ago - Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis - Business Wire
- 5 weeks ago - Kezar Life Sciences halts mid-stage trial for lupus treatment - Reuters
- 5 weeks ago - Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients - Business Wire